The Lazzaro Spallanzani National Institute for Infectious Diseases (Italian: Istituto nazionale per le malattie infettive "L. Spallanzani") is an infectious disease hospital in the Italian city of Rome. The institute is named for the eighteenth-century Italian biologist Lazzaro Spallanzani.^{[citation needed]}

You can help expand this article with text translated from the corresponding article in Italian. (January 2023) Click [show] for important translation instructions. Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Italian Wikipedia article at [[:it:Istituto nazionale per le malattie infettive]]; see its history for attribution. You should also add the template {{Translated|it|Istituto nazionale per le malattie infettive}} to the talk page. For more guidance, see Wikipedia:Translation.

It is the Italian national reference center for Ebola patients.^[1]

During the COVID-19 pandemic, the Spallanzani Institute was the first research centre in Europe to isolate the genomic sequence of SARS-CoV-2 and upload it to GenBank.^[2] The team was composed of Maria Rosaria Capobianchi, Francesca Colavita, and Concetta Castilletti.^[3]

The institute is working with biotech company ReiThera to test a COVID-19 vaccine candidate called GRAd-COV2, which is based on a modified gorilla adenovirus vector.^[4]